Balloon Ostial Dilation (Balloon Sinuplasty)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines BCBSNC coverage and medical necessity criteria for balloon ostial dilation (balloon sinuplasty) of the frontal, maxillary, and sphenoid sinuses for commercial members and related provider requirements.
When Covered section updated with new criterion which states, “The management of nasal airway obstruction in individuals who do not otherwise meet criteria for recurrent acute or chronic sinusitis.”
Criterion #3 in the When Covered section was updated to define abnormal CT as radiographic documentation of persistent inflammation (examples listed).
Policy Guidelines clarified that if an in-office CT is performed by the ENT, an independent radiologist interpretation and possible submission of CT images may be required.
When Balloon Ostial Dilation is Covered and Not Covered
When Balloon Ostial Dilation is covered
Covered when ALL of the following are met
See Policy Guidelines for definition of optimal medical therapy (oral antibiotics, intranasal steroids, optional systemic steroids, saline irrigations, decongestants, allergy management) and imaging timing (obtain after maximal medical therapy).
Balloon ostial dilation (BOD) is considered investigational when the coverage criteria in the “When Covered” section are not met for the specific sinus being evaluated. The policy further lists specific clinical situations that are considered investigational, including: management of headache, nasal airway obstruction, or sleep apnea in individuals who do not otherwise meet criteria for recurrent acute or chronic sinusitis; Samter’s triad (aspirin sensitivity); severe sinusitis secondary to autoimmune or connective tissue disorders (for example, sarcoidosis or Granulomatosis with polyangiitis); severe sinusitis due to ciliary dysfunction (for example, cystic fibrosis); inability to tolerate local/topical anesthetic; a history of a prior failed balloon procedure in the sinus to be treated; sinusitis with extensive fungal disease; isolated ethmoid sinus disease; mucous retention cysts/mucocele; and significant neo-osteogenesis.
Any balloon ostial dilation performed without meeting the specified medical necessity criteria — including required imaging evidence and documentation of prior optimal medical therapy — is considered investigational / not medically necessary. Procedures that lack the documented indications required by the policy (for the specific sinus or patient) are subject to denial as investigational.
Prior Authorization, Documentation, and Procedural Requirements
Prior authorization and applicable CPT codes
Prior authorization/medical necessity review may be required for balloon ostial dilation; applicable CPT codes include 31295, 31296, 31297, and 31298. BCBSNC may request submission of medical records and imaging to determine medical necessity.
Require attempted optimal medical therapy before BOD
Optimal medical therapy must have been attempted and failed before balloon ostial dilation is considered. Optimal medical treatment components are specified and imaging is generally obtained after maximal medical therapy.
- Oral antibiotics: 2 weeks for chronic rhinosinusitis with endoscopic evidence of bacterial infection, or multiple 1–2 week courses for recurrent acute rhinosinusitis
- Intranasal steroids for at least one month
- Systemic steroids at physician discretion
- Saline irrigations (optional); topical/systemic decongestants (optional if not contraindicated)
- Treatment of concomitant allergic rhinitis (pharmacotherapy, avoidance, and/or immunotherapy as appropriate)
Submit CT imaging and radiologist interpretation when requested
BCBSNC may require CT images and an independent radiologist interpretation documenting inflammation of each sinus to be dilated; the Plan may request submission of or access to the CT images for review.
- If an in-office CT is performed by the ENT, an independent radiologist interpretation may be required
- Objective evidence of inflammation on CT imaging is necessary in addition to sinonasal symptoms
Investigational indications that may trigger denial
Procedures that do not meet the medical necessity criteria, or that fall under specified investigational situations, may be considered investigational and risk denial.
- Management of headache, nasal airway obstruction, or sleep apnea when criteria for recurrent acute or chronic sinusitis are not met
- Samter’s triad (aspirin sensitivity)
- Severe sinusitis from autoimmune/connective tissue disorders (e.g., sarcoidosis, GPA) or ciliary dysfunction (e.g., cystic fibrosis)
- Contraindication to or inability to tolerate local/topical anesthetic
- History of prior failed balloon in the sinus to be treated
- Sinusitis with extensive fungal disease, isolated ethmoid disease, mucous retention cysts/mucocele, or significant neo-osteogenesis
Applicable Service Codes
Key Definitions
Clinical Background
Chronic rhinosinusitis (CRS) affects a substantial portion of adults and is initially managed with medical therapy. Initial management typically includes antibiotics, saline nasal irrigations, decongestants as appropriate, and intranasal or systemic steroids. Balloon ostial dilation (also called balloon sinuplasty) is an alternative to functional endoscopic sinus surgery for selected patients with recurrent acute or chronic sinusitis of the frontal, maxillary, or sphenoid sinuses and may be performed as a standalone procedure or adjunctively. The policy requires that optimal medical therapy be attempted and failed before BOD is considered; examples of optimal therapy include appropriate-duration antibiotics (for CRS with endoscopic evidence, typically at least 2 weeks, or multiple 1–2 week courses for recurrent acute disease), intranasal steroids for at least one month, saline irrigations, and other supportive measures.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.